摘要
目的检测下肢动脉粥样硬化(LEAD)患者血清单核细胞趋化蛋白-1(MCP-1)的水平,探讨血清MCP-1对LEAD的诊断价值。方法将选取的163例研究对象按照踝肱指数(ABI)值分成LEAD组和非LEAD组,采用酶联免疫吸附法测定血清MCP-1水平,并分析其与LEAD危险因素的相关性;应用ROC曲线分析血清MCP-1对LEAD的诊断价值。结果 LEAD组血清MCP-1水平明显高于非LEAD组(P<0.05);血清MCP-1浓度与心率、收缩压、舒张压呈正相关,而与甘油三酯呈负相关(P<0.05);以血清MCP-1浓度作为诊断LEAD的指标,ROC曲线下面积为0.801(P<0.05),其诊断临界点为131.50 pg/ml。结论血清MCP-1对LEAD的诊断价值中等,可考虑作为诊断LEAD的生物学指标之一。
Objective To detect the levels of serum monocyte chemotactic protein-1（MCP-1） and explore the diagnostic value of serum MCP-1 in patients with lower extremity atherosclerosis（LEAD）. Methods The 163 patients selected as research subjects were divided into LEAD group and non-LEAD group according to the ankle brachial index（ABI） value. The levels of serum MCP-1 were determined by enzyme-linked immunosorbent assay（ELISA）, and the correlation with risk factors of LEAD was analyzed. ROC curve was drawn to analyze the value of serum MCP-1 in diagnosis on LEAD. Results The levels of serum MCP-1 in the LEAD group was significantly higher than that in the non-LEAD group（P 0.05）; the concentration of serum MCP-1 is positively correlated with the heart rate（HR）, systolic blood pressure（SBP）, and diastolic blood pressure（DBP） while negatively correlated with triglyceride（P 0.05）. The concentration of serum MCP-1 was taken as a diagnostic index of LEAD, the area under ROC curve was 0.801（P 0.05）,and the critical point for diagnosis was 131.50 pg/ml. Conclusion The serum MCP-1 has moderate value in diagnosis on LEAD, and it can be considered as one of the biological indicators in diagnosis on LEAD.
出处
《西南国防医药》
CAS
2017年第1期17-20,共4页
Medical Journal of National Defending Forces in Southwest China
关键词
单核细胞趋化蛋白-1
下肢
动脉粥样硬化
诊断
monocyte chemotactic protein-1
lower extremity
atherosclerosis
diagnosis
